Description

Axsome Therapeutics: Initiation of Coverage- Auvelity, Sunosi & SYMBRAVO Fueling A Multi-Product Growth Engine!

Axsome Therapeutics reported strong first-quarter 2026 results highlighted by robust revenue growth driven by its three commercial products: Auvelity, Sunosi, and SYMBRAVO. Total revenue reached $191.2 million, marking a 57% year-over-year increase. Auvelity accounted for the majority of this revenue with net product sales climbing 59% to $153.2 million, reflecting sustained demand and growth in market share. Sunosi and SYMBRAVO also exhibited positive trends, with revenues increasing 34% and 36% respectively, though SYMBRAVO’s gross-to-net discounts remain elevated in the high 70% range, indicating ongoing challenges in market access and payer negotiations. The company expanded its commercial infrastructure notably, with the Auvelity sales force growing to about 630 representatives to support launches in multiple indications, including the newly FDA-approved indication for agitation associated with Alzheimer’s disease (ADA).